LondonAccording to a new study, three doses of the Kovid vaccine can prevent hospitalization when exposed to the Omicron variant. Preliminary investigations have shown that the two-dose covid vaccine is less effective against the Omicron variant than the previous variants such as Delta.
As a result, many countries have started booster doses. India will also start the third dose campaign for health workers and elderly people from January 10.
A study led by the UK Health Security Agency (UKHSA) estimates the effectiveness of three doses of either Pfizer, Moderna and AstraZeneca’s COVID-19 vaccines against mild and severe disease in adults 65 years of age or older. has been applied.
The study included individuals who reported symptoms in a community test between November 27 and December 31, 2021. Vaccination rates in PCR positive cases were compared with vaccination rates in those who tested negative.
Estimates suggest that effectiveness with the Omicron variant is significantly lower than with the delta variant and decreases more rapidly in people 65 years of age or older.
But a third dose of a COVID vaccine after 2 to 9 weeks was associated with an 89 percent lower risk of hospitalization in people 65 years of age or older with the Omicron variant.
Professor Wei Shen Lim, President of JCVI COVID-19 Vaccination, said, “The current data shows that the booster dose is capable of providing a high level of protection against serious disease, even for the most vulnerable age groups. “
“The data are highly encouraging and emphasize the value of booster doses,” Lim said.
However, the UKHSA has denied campaigning for a second booster dose. In the wake of the highly infectious Omicron variant, which is causing an increasing number of infections worldwide, Israel has launched a fourth COVID shot, while some countries including Germany, France and the UK are planning for it.
The JCVI advised that priority should be given to the first booster dose for all age groups.
first published:Jan. 9, 2022, 6:01 p.m.